CURE Pharmaceutical and United Smart Cities launch healthcare initiative
CURE Pharmaceutical, an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities…
CURE Pharmaceutical to acquire privately-held Chemistry Holdings Inc., expanding its technology platform in oral drug delivery
Oxnard-based CURE Pharmaceutical announced plans to acquire formulation technology company Chemistry Holdings Inc. in an all-stock transaction. The deal will allow…
CURE Pharmaceutical expands DEA license to manufacture cannabinoid molecules
CURE Pharmaceutical announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD).